



CASE D0020 NP

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV306636575US
Express Mail Label Number

September 17, 2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1646

FEDER ET AL.

Examiner: JIANG, DONG

APPLICATION NO: 09/932,145

FILED: AUGUST 17, 2001

FOR: NOVEL IMIDAZOLINE RECEPTOR HOMOLOGS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT WITHOUT TRAVERSE

Sir:


In reply to the Office Action dated August 18, 2003, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention embraced by the claims of Group III, without traverse, drawn to a purified polynucleotide, a vector containing the same, a host cell thereof, and a method of recombinantly producing the encoded polypeptide.

The Office Action further directs Applicants to elect a single disclosed polynucleotide sequence. Applicants hereby provisionally elect, without traverse, the polynucleotide of Group A directed to the isolated polynucleotide of SEQ ID NO:3 encoding the polypeptide of SEQ ID NO:4.

Applicants Reply is timely submitted and no extensions of time are required. If any fee is due in connection herewith, please charge such fee to Deposit Account No. 19-3880 of the undersigned. Furthermore, if any extension of time not already accounted for is required, such extension is hereby petitioned for, and it is requested that any fee due for said extension be charged to the above-stated Deposit Account.

Respectfully submitted;

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5289
Date: September 17, 2003


Stephen C. D'Amico
Attorney for Applicants
Reg. No. 46,652